Literature DB >> 17532672

Pioglitazone Improves Diabetic Dyslipidaemia in Patients with Type 2 Diabetes Mellitus with or without Lipid-Lowering Therapy.

Christof Schöfl1, Georg Luebben.   

Abstract

Entities:  

Year:  2005        PMID： 17532672     DOI： 10.2165/00044011-200525050-00007

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  18 in total

1.  Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study.

Authors:  Gerd Assmann; Paul Cullen; Helmut Schulte
Journal:  Circulation       Date:  2002-01-22       Impact factor: 29.690

2.  Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.

Authors:  D Einhorn; M Rendell; J Rosenzweig; J W Egan; A L Mathisen; R L Schneider
Journal:  Clin Ther       Date:  2000-12       Impact factor: 3.393

3.  The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.

Authors:  S Rosenblatt; B Miskin; N B Glazer; M J Prince; K E Robertson
Journal:  Coron Artery Dis       Date:  2001-08       Impact factor: 1.439

4.  Insulin sensitivity and acute insulin response in African-Americans, non-Hispanic whites, and Hispanics with NIDDM: the Insulin Resistance Atherosclerosis Study.

Authors:  S M Haffner; G Howard; E Mayer; R N Bergman; P J Savage; M Rewers; L Mykkänen; A J Karter; R Hamman; M F Saad
Journal:  Diabetes       Date:  1997-01       Impact factor: 9.461

Review 5.  Diabetes and atherosclerosis: an epidemiologic view.

Authors:  K Pyörälä; M Laakso; M Uusitupa
Journal:  Diabetes Metab Rev       Date:  1987-04

6.  Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.

Authors:  J Rosenstock; D Einhorn; K Hershon; N B Glazer; S Yu
Journal:  Int J Clin Pract       Date:  2002-05       Impact factor: 2.503

7.  Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.

Authors:  Karl Winkler; Thomas Konrad; Stefanie Füllert; Isolde Friedrich; Ramadan Destani; Manfred W Baumstark; Kristin Krebs; Heinrich Wieland; Winfried März
Journal:  Diabetes Care       Date:  2003-09       Impact factor: 19.112

Review 8.  The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes.

Authors:  J B Buse; M H Tan; M J Prince; P P Erickson
Journal:  Diabetes Obes Metab       Date:  2004-03       Impact factor: 6.577

9.  One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

Authors:  Markolf Hanefeld; Paolo Brunetti; Guntram H Schernthaner; David R Matthews; Bernard H Charbonnel
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

10.  A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.

Authors:  Matthias Herz; Don Johns; Jesus Reviriego; Loren D Grossman; Chantal Godin; Santiago Duran; Federico Hawkins; Heather Lochnan; Fernando Escobar-Jiménez; Philip A Hardin; Christopher S Konkoy; Meng H Tan
Journal:  Clin Ther       Date:  2003-04       Impact factor: 3.393
View more
  1 in total

Review 1.  Pioglitazone for type 2 diabetes mellitus.

Authors:  B Richter; E Bandeira-Echtler; K Bergerhoff; C Clar; S H Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.